echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > DMD Shanghai Institute of Materia Medica Pan Guoyu's research group won the 2021 James R. Gillette Best Paper Award

    DMD Shanghai Institute of Materia Medica Pan Guoyu's research group won the 2021 James R. Gillette Best Paper Award

    • Last Update: 2022-05-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    The primary human hepatocytes (PHHs) model is the gold standard for evaluating hepatic metabolism and disposal of drugs, however, PHHs have limited sources, cannot proliferate in vitro, and rapidly lose their function during culture
    These problems limit its widespread use
    In 2021, Pan Guoyu's group from Shanghai Institute of Materia Medica, Chinese Academy of Sciences published a paper entitled "Functional Proliferating Human Hepatocytes: In Vitro Hepatocyte Model for Drug Metabolism, Excretion , and Toxicity”, reported the potential of organoids of novel proliferating hepatocyte-like cells, ProliHHs (Proliferating Human Hepatocytes), in drug metabolism, transport, and safety evaluation
    Using the latest primary hepatocyte degeneration technology, the study uses the hepatocyte-like cell ProliHHs with a certain expansion ability generated from PHH as a substitute for primary human hepatocytes to study the prediction of hepatic clearance rate and bile duct excretion index of drugs.
    and hepatotoxicity, etc.
    , and compared the differences between conventional cell models and organoid models in ADMET work
    In 2022, the paper was named the best academic paper of the DMD year (2021) by the ASPET annual meeting jury from hundreds of papers, and won the James R.
    Gillette Award
    The first authors of the paper are postgraduate students Qiao Shida and Dr.
    Feng Sisi
    This work is supported by the pilot project of the Chinese Academy of Sciences and the National Natural Science Foundation of China
    Figure 1.
    (a) ProliHHs-P: 2D cultured prolifable ProliHHs; ProliHHs-M: 3D cultured ProliHHs organoids; (b) ProliHHs-M classical drug clearance study; (c) ProliHHs-M drug bile Excretion study; (d) Hepatotoxicity prediction study of ProliHHs
    Figure 2.
    (a) James R.
    Gillette Best Paper Certificate; (b) ASPET Annual Conference Report Video (screenshot)
    (Contributed by: Pan Guoyu's research group) 
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.